The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of dovitinib in first line metastatic or (non resectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011-03.
Jesús García-Donas
Research Funding - Novartis
Susana Hernando Polo
No relevant relationships to disclose
Marta Guix
No relevant relationships to disclose
Miguel Angel Climent Duran
No relevant relationships to disclose
María José Méndez-Vidal
No relevant relationships to disclose
Paula Jiménez-Fonseca
No relevant relationships to disclose
Nuria Laínez
No relevant relationships to disclose
Luis Leon Mateos
No relevant relationships to disclose
Fernando Moreno
No relevant relationships to disclose
Eduardo Raul Segura Gonzalez
No relevant relationships to disclose
Ignacio Duran
No relevant relationships to disclose
Francisco Javier Perez
No relevant relationships to disclose
Juan Francisco Rodriguez-Moreno
No relevant relationships to disclose
Sonia Maciá
No relevant relationships to disclose
Sergio Vazquez-Estevez
No relevant relationships to disclose
Jose Angel Arranz
No relevant relationships to disclose
Daniel E. Castellano
No relevant relationships to disclose
Cristina Rodriguez de Antona
No relevant relationships to disclose